BELLUS Health Inc (TSE:BLU) was down 1.3% on Wednesday . The company traded as low as C$8.74 and last traded at C$9.10, approximately 40,150 shares changed hands during mid-day trading. A decline of 35% from the average daily volume of 62,139 shares. The stock had previously closed at C$9.22.
The company has a debt-to-equity ratio of 0.15, a current ratio of 14.10 and a quick ratio of 13.97. The company has a fifty day moving average of C$8.94 and a 200-day moving average of C$5.96. The firm has a market capitalization of $510.59 million and a PE ratio of -16.08.
BELLUS Health Company Profile (TSE:BLU)
BELLUS Health Inc, a clinical-stage biopharmaceutical company, develops novel therapeutics for conditions with high unmet medical need. Its lead drug candidate includes BLU-5937, a small molecule antagonist of the P2X3 receptor for chronic cough. The company also has economic interests in various partnered development stage programs, including KIACTA for the treatment of sarcoidosis; AMO-01 for treatment of Phelan McDermid syndrome; and ALZ-801 for APOE4 homozygous Alzheimer's disease.
See Also: What does an outperform rating mean?
Receive News & Ratings for BELLUS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BELLUS Health and related companies with MarketBeat.com's FREE daily email newsletter.